Navigation Links
Mast Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results
Date:3/19/2013

nse, offset by a $0.9 million decrease in consulting fees and legal expenses.

Balance Sheet Highlights
As of December 31, 2012, the Company had cash, cash equivalents and short-term investments totaling $36.5 million. Stockholders' equity amounted to $41.8 million as of December 31, 2012.  The Company's contingent asset related to the consideration for the acquisition of SynthRx in April 2011 was settled in December 2012.  The Company recorded the fair value of the contingent asset as of the settlement date as an adjustment to equity and recognized as a transaction-related expense the increase in its fair value as of its settlement date relative to December 31, 2011.

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, CA.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs.  MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow). 

The Company is recruiting subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease.  The Company plans to initiate a phase 2 clinical study of MST-188 in acute limb ischemia, a complication of peripheral arterial disease, in late 2013 or early 2014.  More information can be found on the Company's web site at www.masttherapeutics.com.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are
'/>"/>

SOURCE Mast Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Echo Therapeutics Achieves ISO 13485 Certification
2. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
3. Echo Therapeutics Appoints Robert Doman to Board of Directors
4. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
5. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
6. Cell Therapeutics to Present at the ROTH Capital Partners 25th Annual Growth Stock Conference
7. PTC Therapeutics Closes $60 Million Private Financing
8. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
9. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
10. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... 4,396.20, down 0.52%, the Dow Jones Industrial Average finished the ... at 1,964.68, down 0.41%. The losses were broad based as ... The S&P 500 Health Care Sector Index ended the day ... in the last one month. Investor-Edge has initiated coverage on ...
(Date:7/11/2014)... SAN DIEGO , July 11, 2014 ... Therapies Corp. ("Biotie") to end the option held by ... to commence further development of NRL-1 (intranasal diazepam) for ... seizures. Over the past year, Biotie has ... Neurelis in preparation for the pivotal clinical work required ...
(Date:7/10/2014)... -- Integrated Silicon Solution, Inc. (Nasdaq: ISSI ... solutions, today announced that it will host its earnings ... a.m. Pacific Time (10:00 a.m. Eastern Time) to discuss ... quarter ended June 30, 2014. To access ... a.m. Pacific time on July 24, 2014.  The participant ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... PRINCETON, N.J., April 5, 2012  In conjunction with its first quarter 2012 ... 2012), Covance Inc. (NYSE: CVD ) is pleased to invite ... broadcast live over the Internet on Thursday, May 3, 2012 at 9:00 ... First Quarter 2012 Earnings Webcast and Slide Presentation , , , ...
... SPRING, Md., April 4, 2012   Sunpeaks Ventures, ... or "Sunpeaks Ventures") and its wholly owned subsidiary ... announce that HDS has signed a marketing and ... Partners and Skyrock ("AACSA Partners/Skyrock") to distribute and ...
Cached Medicine Technology:Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores 2Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores 3
(Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed ... diagnosed incident cases in 2013 to 11,568 diagnosed incident ... of 4.35%, during the forecast period. In 2023, the ... cases of aGVHD in the 6MM, with 4,989 diagnosed ... of diagnosed incident cases of aGVHD, with 704 diagnosed ...
(Date:7/13/2014)... 2014 A decreased ability to identify odors ... Alzheimer,s disease, while examinations of the eye could ... with Alzheimer,s, in the brain, according to the ... the Alzheimer,s Association International Conference 2014 (AAIC 2014) ... the decreased ability to identify odors was significantly ...
(Date:7/13/2014)... Wright & Schulte LLC has learned that ... July of 2015, in U.S. District Court, District of ... discovery process in the South Carolina federal court ... the multidistrict litigation (MDL). The complaints pending in the ... allege that they took the statin medication to lower ...
(Date:7/13/2014)... Celebrity fitness trainer and former World Super ... with Aqua Health Labs for their flagship product PhytOriginal, ... The collaboration was recently announced live on ESPN Radio. ... actor, model, and a two time World Super Middleweight ... has prepared stars including Demi Moore, Hilary Swank and ...
(Date:7/13/2014)... Palatine, Illinois (PRWEB) July 13, 2014 Hope ... facilitating a monthly grief support group at the Tamarack Senior ... will be held at 10:30 A.M. on the 3rd Wednesdays ... July 16th, 2014 at the Tamarack Community located at 55 ... to all bereaved individuals and there is no cost for ...
Breaking Medicine News(10 mins):Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... known that HIV patients are at an increased risk of ... shows // aggressive antiretroviral therapy may help lower that risk. ... therapy was associated with a lower incidence of Kaposi sarcoma ... more than 7,300 patients infected with HIV and the data ...
... In a study published in Diabetes Care, March 2005, scientists ... ,Insulin sensitivity is the measure for the risk ... then he has a lower risk of heart problems. ... insulin to control blood sugar. As this happens the body ...
... and heart attack can be reduced for heart patients undergoing ... of an anti-clotting drug before the procedure is the answer.// ... catheter is threaded into an artery. The balloon is inflated ... A small synthetic tube - stent is used to hold ...
... is known to help in controlling obesity. A new study ... Obesity (2005) says that dietary calcium present in the yogurt ... in lipid utilization and decrease in lipogenesis. ... one group was put on balanced deficit diets and the ...
... standard treatment with levodopa can reduce the amount of ... fluctuations they experience during the day . ,For ... drug entacapone, which must be taken with every levodopa ... of the additional drugs were effective in reducing the ...
... being hailed by researchers for its ability to target cancer ... called ON01910 works by interfering with a molecule known as ... multiply. This molecule is found in higher numbers in cancerous ... have especially high amounts. ,The drug was tested ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: